Adult Vaccinations

NOIDA: Bacillus Calmette-Guerin (BCG) vaccine used for treatment of tuberculosis helps as a preventive for Covid infection, as it acts as a controlling agent, a study titled “Role of BCG Vaccination in Prevention of Covid 19 Infection Among Healthcare Workers” has said. The paper was submitted by Dr Renu Agrawal, medical superintendent, Noida Covid Hospital, and her team in the peer reviewed Indian Journal of Applied Research (IJAR). The World Health Organisation, however, has not recommended the vaccine for Covid prevention and has said it may lead to a false sense of security. The study, which is the first such research from Noida on the subject, was published on November 4. It was conducted on 140 healthcare workers on Covid duty at Noida Covid Hospital, the district hospital and the Super Specialty Paediatric Hospital and Post Graduate Teaching Institute (SSPHPGTI). The study was conducted in two batches and a 150-member control group was created for it. While 80 people were g...

MarketsandResearch.biz has added a new intelligence research report entitled Global Tuberculosis Vaccine Treatment Market 2020 by Manufacturers, Countries, Type and Application, Forecast to 2026 to its collection of top-line market research reports. The report presents a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution and recent developments in both historic and present contexts. The report reveals the latest market insights, current situation analysis with upcoming trends, and breakdown of the products and services. The report covers an in-depth analysis of the overall growth prospects in the market. It focuses on key statistics on the market status, size and share growth factors of the global Tuberculosis Vaccine Treatment market. A comprehensive analysis of this market included in this report will provide access to direct first-hand insights on the growth trail of the market in the near term and long term. The repor...

A tuberculosis (TB) vaccine given to more than 100 million babies each year could help adults fight coronavirus, health experts have said, after trials showed it stimulates the immune system. Advertisement

A tuberculosis (TB) vaccine given to more than 100 million babies each year could help adults fight coronavirus, health experts have said, after trials showed it stimulates the immune system. Some 10,000 people in the UK will be recruited to investigate whether the Bacillus Calmette-Guerin (BCG) vaccine could help people battle coronavirus until more effective vaccines are found. Australia, the Netherlands, Spain and Brazil are involved in the programme, the UK's arm of which is being led by the University of Exeter. Professor John Campbell, of the university's medical school, said: "BCG has been shown to boost immunity in a generalised way, which may offer some protection against COVID-19 ." Researchers are hoping, he said, to confirm whether the BCG vaccine could help protect people who are at risk of COVID-19. Advertisement "If it does, we could save lives by administering or topping up this readily available and cost-effective vaccination,...

“It takes 10 to 15 years to create and really develop a vaccine, so how do you get something together that can deal with a pandemic in months?” says Cirillo. “That’s the place where we started looking around.” A race against the clock began immediately, and in April his team at Texas A&M, plus scientists and doctors at the University of Texas MD Anderson Cancer Center, the Baylor College of Medicine, the Harvard School of Public Health, and Cedars-Sinai Medical Center in Los Angeles, found a needle in a haystack. The discovery? Evidence indicated that one of the most widely used vaccines in the world—BCG, which prevents people from contracting tuberculosis—might be employed to lessen the effects of Covid-19. It could potentially mean fewer hospitalizations and deaths. BCG, formally Bacille Calmette-Guérin, is something of a miracle vaccine. First used to treat tuberculosis in 1921, it’s still the only vaccination available to ward off the disease, which killed indiscriminately ...

While global attention is sharply focussed on the progress of COVID-19 vaccines going through various phases of clinical trials worldwide, some public institutions in India and a private player - Serum Institute of India - are attempting to see if a time-tested tuberculosis vaccine  - Bacillus Calmette Guerin (BCG) vaccine - can control the severity, or even delay or prevent, the novel coronavirus infection.   The Clinical Trial Registry of India lists at least five clinical trial proposals sponsored by Indian Council of Medical Research (ICMR), Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Maharashtra Medical Education and Drugs Department and Serum Institute of India to see BCG vaccine's impact on COVID infection. One trial, sponsored by ICMR and planned in AIIMS, New Delhi, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGI), Lucknow and  School of Tropical Medicine, Kolkata attempts to see if BCG vaccination in the 18 to...

Credit: CC0 Public Domain A study of older mice with type 2 diabetes has yielded highly promising results for researchers investigating potential new vaccines for tuberculosis (TB). A team of researchers from Australia, Bangladesh and France investigated a potential vaccine, BCG::RD1, and found it highly protective when administered directly into the lungs of diabetic mice, which were then exposed to TB. According to the World Health Organisation, TB is one of the top 10 causes of death world-wide, and the leading cause from a single infectious agent. The only currently licensed vaccine, BCG, is not effective in adults. "These findings are especially welcome because type 2 diabetes is not just a significant risk factor for TB, it's a risk factor that becomes more widespread every year in our aging population," said senior author Dr. Andreas Kupz, a Senior Research Fellow at the Australian Institute of Tropical Health and Medicine (AITHM) at James Cook University...

JERUSALEM, Aug. 10 (Xinhua) -- Israeli researchers have found that vaccinations against tuberculosis may provide additional protection against COVID-19, Ben Gurion University (BGU) in southern Israel said Monday. In a study published in the journal Vaccines, researchers from BGU and the Hebrew University of Jerusalem analyzed the correlation between BCG vaccine for tuberculosis and COVID-19 outcomes. It was found that countries that widely administered BCG are associated with some protection against COVID-19, reducing infection and death rates. The protection was significant among those 24 years old and younger who had received the vaccination in the last 15 years. The team analyzed data from 55 countries, which comprise 62.9 percent of the world's population and found a strong negative correlation between the years of BCG administration and COVID-19 deaths per million (DPM) along with the progress of the pandemic. Furthermore, results from multivariable regression tests with ...

A new study found evidence that a vaccine used against tuberculosis may help reduce the death rate for COVID-19. The vaccine, called bacillus Calmette−Guérin (BCG), likely provides nonspecific immunity, meaning protection against other diseases, although the mechanisms are still unclear, the researchers said. They found through statistical analysis that countries where BCG is widely administered have a lower COVID-19 mortality rate when other factors are accounted for. Get The Times of Israel's Daily Edition by email and never miss our top stories Free Sign Up A 10 percent increase in the BCG index, which estimates the degree of vaccination in the country, was correlated with a 10.4% reduction in mortality from the coronavirus. The paper emphasized that further research is needed and the results “should be considered with caution.” Vaccination trials will be needed to corroborate the findings, the researchers wrote. The World Health Organization has cautioned against using the...

(Reuters) - The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. FILE PHOTO: The ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV), which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, U.S. January 29, 2020. Alissa Eckert, MS; Dan Higgins, MAM/CDC/Handout via REUTERS Tuberculosis vaccine may limit COVID-19 deaths A tuberculosis vaccine routinely given to children in countries with high rates of that bacterial disease might be helping to reduce deaths from COVID-19, researchers reported on Thursday in the scientific journal Proceedings of the National Academy of Sciences. After accounting for differences in factors that might affect vulnerability to t...

Reviewed by Emily Henderson, B.Sc. Jul 8 2020 One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected. Research by Assistant Professor Luis Escobar of the College of Natural Resources and Environment and two colleagues at the National Institutes of Health suggests that Bacille Calmette-Guérin (BCG), a tuberculosis vaccine routinely given to children in countries with high rates of tuberculosis infection, might play a significant role in mitigating mortality rates from COVID-19. Their findings have been published in the Proceedings of the National Academy of Sciences. In our initial research, we found that countries with high rates of BCG vaccinations had lower rates of mortality. But all countries are different: Guatemala has a younger population than, say, Italy, so we had to make adjustments to the data to accommodate those differences....

Luis Escobar, pictured, and two colleagues at the National Institutes of Health collected coronavirus mortality data from around the world. Photo courtesy of Luis Escobar for Virginia Tech. Credit: Virginia Tech One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected. Research by Assistant Professor Luis Escobar of the College of Natural Resources and Environment and two colleagues at the National Institutes of Health suggests that Bacille Calmette-Guérin (BCG), a tuberculosis vaccine routinely given to children in countries with high rates of tuberculosis infection, might play a significant role in mitigating mortality rates from COVID-19. Their findings have been published in the Proceedings of the National Academy of Sciences . "In our initial research, we found that countries with high rates of BCG vaccinations had lower rates...

BCG Vaccine Description Bacille Calmette-Guerin (BCG) vaccine is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. The TICE® strain used in this BCG vaccine preparation was developed at the University of Illinois from a strain originated at the Pasteur Institute. The BCG is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections and in vivo studies, and reported morbidity and mortality reductions as high as 70%. The NIH says the BCG vaccine is a fairly safe vaccine and it is not associated with severe complications. Many foreign-born persons have been BCG-vaccinated. As an example, India, with the world's highest TB burden, introduced BCG in mass immunization beginning in 1948. TB is the leading cause of death from infectious disease worldwide, causing about 1.3 million deaths per year, mostly in the developing world. The respi...

Using the TB vaccine as a vehicle In BCG:CoVac, the BCG vaccine is used as a vehicle to deliver distinctive proteins that originate from the SARS-CoV-2 virus surface. The goal is for the human immune system to develop a memory of SARS-CoV-2 and develop immunity. There is currently global interest in the BCG vaccine, which is being investigated in ongoing clinical trials as a possible intervention to protect vulnerable people during the COVID-19 pandemic. This is because of suggestions the BCG vaccine has other beneficial effects on the immune system that could protect against other infections. A 2019 observational study reported the vaccine is related to fewer deaths from certain infections other than from TB in low-income countries. However, current COVID-19 related studies only investigate the protective effects of the BCG vaccine by itself. Dr Claudio Counoupas, research scientist at the Centenary Institute and co-lead on the project, said: “Combining a part of the SARS-CoV-2 ...

Tuberculosis Vaccine Treatment Market report published by Value Market Research is an in-depth analysis of the market covering its size, share, value, growth and current trends for the period of 2019-2026 based on the historical data. This research report delivers recent developments of major players with their respective market share. In addition, it also delivers detailed analysis of regional and country market. The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the tuberculosis vaccine treatment market include GlaxoSmithKline Plc, GreenSignal Bio Pharma Limited, IDT Biologics GmbH, Merck & Co., Inc., Sanofi Pasteur SA, Serum Institute Of India Pvt. Ltd and Taj Pharmaceuticals Limited among others. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product ...

Dr. H. Satria Arief Prabowo, an alumnus of Universitas Airlangga, started taking part in the tuberculosis vaccine development team while undergoing research training in Groningen, the Netherlands in 2012. He continued the research during his doctoral program at the London School of Hygiene and Tropical Medicine, UK. Shortening TB therapy from 6 to 1 Month Through a research consortium funded by the European Union, Satria’s project aims to develop therapeutic vaccinations for TB sufferers. This approach is quite unique because vaccinations generally given to prevent disease can also be given to patients who are already sick to awaken the immune system. Moreover, the vaccination has the potential to shorten the treatment period of TB sufferers. “Our target of TB therapy can be shortened from 6 months to 1 month, and that will have a big impact so that the TB disease rate can be reduced significantly in the world,” he continued. The vaccine development was completed at the end of 201...

Tuberculosis Vaccine Market Report Global analysis report is very helpful in understanding the Tuberculosis Vaccine market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better. The current market is evolving its presence and some of the major players in the study are  GlaxoSmithKline, Sanofi Pasture, Longcom Enterprise Ltd, Biofabri, Valneva plc, and Archivel Farma S.L.. The Tuberculosis Vaccine Market research study will give the answer to questions about the present performance of the market and the competitive scope, opportunity, challenges, cost, and more. The market can be divided based on produc...

It comes as NSW recorded seven new coronavirus cases of COVID-19 in return travellers while more than 17,000 people were tested for the disease, the second-highest daily total in the state. Meanwhile in Victoria, health experts warn the state could be on the "tipping point" for a second wave of infections after the state recorded 52 new cases in the past three days, with 13 new cases confirmed on Friday. The majority of those new cases were community transmission, with four linked to a cluster at the Stamford Plaza Hotel. NSW Health Minister Brad Hazzard said while it was fortunate all seven new cases in NSW were in travellers in hotel quarantine, it was worrying to see ongoing community spread in other states. "We remain concerned about the possibility of that transmission of COVID-19 escalating," he said. Loading Despite the continuing detection of community cases in Victoria, Mr Hazzard said he backed Premier Gladys Berejiklian’s view that all state and...

Table of Contents According to a new study published in Cell Host & Microbe, a vaccine against tuberculosis (TB) that has been around for about a century can offer protection against other infections as well. BCG Vaccine Researchers from the University of Bonn and the Radboud University Medical Center, Nijmegen, in collaboration with counterparts from Australia and Denmark, have found that the BCG vaccine bolsters the immune system. BCG is an abbreviation for Bacillus Calmette-Guerin, the bacterium responsible for tuberculosis. Read Also: Tuberculosis Vaccine (BCG) Could Help the Immune System Fight COVID 19 The BCG vaccine was first used medically in 1921. A hundred years after, it offers the only effective vaccination against the microbe causing TB. Evidence suggests that the TB vaccine seems to enhance the immunity of patients. Scientists have only been unable to explain why this is the case before now. People vaccinated with this biological preparation were found...